Elevai Labs, Inc. (NASDAQ:ELAB) Short Interest Down 89.6% in February

Elevai Labs, Inc. (NASDAQ:ELAB) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 19,400 shares, a decline of 89.6% from the February 13th total of 185,700 shares. Based on an average trading volume of 302,600 shares, the short-interest ratio is currently 0.1 days. Currently, 0.6% of the shares of the stock are sold short.

Elevai Labs Trading Up 6.6 %

NASDAQ ELAB traded up $0.26 on Friday, reaching $4.18. 58,356 shares of the company were exchanged, compared to its average volume of 105,621. The business’s fifty day moving average price is $11.85 and its 200 day moving average price is $96.32. The stock has a market capitalization of $2.42 million, a P/E ratio of -0.07 and a beta of -2.93. The company has a current ratio of 3.86, a quick ratio of 3.40 and a debt-to-equity ratio of 0.06. Elevai Labs has a fifty-two week low of $3.88 and a fifty-two week high of $1,134.00.

About Elevai Labs

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.